19 January 2024
DEP® cabazitaxel data presentation at ASCO GI cancer meeting
12 January 2024
App 3H - Lapsed Performance Rights
12 January 2024
App 3X - Initial Directors Interest
12 January 2024
App 3G - Issuance of Performance Rights to C Maley
12 January 2024
App 3Z - Final Directors Interest Notice J Fairley
21 December 2023
Appendix 2A
19 December 2023
Positive DEP® docetaxel Phase 2 results
8 December 2023
Change in Director's Interest Notice
8 December 2023
Notification regarding unquoted securities
6 December 2023
Starpharma to present DEP® at Radiopharmaceuticals Summit
30 November 2023
AGM Chairman's address and CEO's presentation
29 November 2023
AGM Results
15 November 2023
Appendix 2A
15 November 2023
Notice of Annual General Meeting 2023 - Clarification
14 November 2023
Starpharma to present at Bell Potter Healthcare Confernce
10 November 2023
Application for quotation of securities
10 November 2023
Appendix 2A
10 November 2023
Starpharma announces new CEO, Ms Cheryl Maley
6 November 2023
Appendix 3G
31 October 2023
Quarterly Activities Report & Appendix 4C

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.